DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.

Expert Opinion on Drug Discovery, published by Taylor & Francis Ltd, is a premier journal dedicated to the rapidly evolving field of drug development and innovation. With a strong emphasis on the integration of multidisciplinary approaches in pharmacology and toxicology, the journal has established itself as an invaluable resource for researchers, professionals, and students alike. Its impressive impact factor and classification as a Q1 journal in drug discovery, alongside its high Scopus ranking (Rank #20/157, Percentile 87th), underscore its significance within the academic community. Spanning from 2006 to 2024, Expert Opinion on Drug Discovery features a wide range of expert reviews and opinion articles that provide insights into the latest trends and breakthroughs in drug discovery, fostering collaboration and knowledge exchange. While the journal is not open access, it plays a critical role in shaping the future of drug development, making it an essential platform for those seeking to deepen their understanding of this dynamic field.

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.

JOURNAL OF PARASITOLOGY is a leading scholarly publication dedicated to the field of parasitology, published by ALLEN PRESS INC. With an impactful history spanning from 1945 to 2024, this journal serves as a vital resource for researchers, professionals, and students interested in the complex interactions between parasites and their hosts. Operating from its base in the United States, this journal holds a Scopus quartile ranking of Q3 in Ecology, Evolution, Behavior and Systematics, Medicine (Miscellaneous), and Parasitology, providing a solid reflection of its impact within these categories. While currently not offering Open Access, the JOURNAL OF PARASITOLOGY continues to encourage the dissemination of pivotal research findings that contribute to our understanding of parasitic diseases and ecological systems, positioning it as an indispensable tool for knowledge advancement in the life sciences.

European Journal of Medicinal Chemistry Reports, published by ELSEVIER, is a vital platform dedicated to advancing the field of medicinal chemistry through open access communication of high-quality research. With an impact factor reflecting its growing influence, this journal has rapidly established a reputation for scholarly excellence since its launch in 2021. It serves as a converging point for innovative studies and reviews that span the disciplines of chemistry and molecular medicine, reflected in its Q2 and Q3 quartile rankings in relevant categories for 2023. Situated in France, the journal is accessible globally, ensuring that researchers, professionals, and students can easily engage with significant findings and methodologies in medicinal chemistry. The open access model facilitates the dissemination of knowledge, bridging gaps between laboratory research and practical applications in drug development. By fostering collaboration and highlighting emerging trends, the European Journal of Medicinal Chemistry Reports plays a crucial role in shaping the future of therapeutic innovations.

Medicinal Chemistry is a prestigious journal published by Bentham Science Publishers Ltd, dedicated to advancing the field of drug discovery and development. Established in 2005 with a converged publication timeframe extending to 2024, this journal serves as a vital resource for researchers and professionals interested in the intricate processes of medicinal chemistry, pharmacology, and toxicology. With an ISSN of 1573-4064 and an E-ISSN of 1875-6638, it has established a notable presence in the academic community, currently positioned in Q3 of Drug Discovery category according to the 2023 quartiles. The journal's ranking in Scopus places it at 90 out of 157 in its field, showcasing its impact and relevance, with a percentile standing of 42. Although the journal is not open access, it continues to provide insightful articles and research findings that contribute significantly to the understanding and innovation in medicinal chemistry. Based in the United Arab Emirates, Medicinal Chemistry is committed to disseminating high-quality research that shapes the future of drug formulation and therapeutic advancement.

Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.

Expert Opinion on Therapeutic Targets, published by Taylor & Francis Ltd, is a highly respected journal in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With a focus on cutting-edge research and innovative approaches to therapeutic development, this journal has established itself as a leading platform for scholars and practitioners, boasting a prestigious Q1 ranking across multiple categories in 2023. The journal aims to present expert perspectives on novel therapeutic strategies, promising drug candidates, and insights into the intricate mechanisms underlying various diseases. Its impressive impact factor reflects the journal's commitment to advancing scientific knowledge and influencing clinical practice. With its inception in 1997 and ongoing publication through to 2024, Expert Opinion on Therapeutic Targets continues to be an invaluable resource for those seeking to stay at the forefront of therapeutic innovations.

Journal of Parasitology Research, published by HINDAWI LTD, is a pivotal open-access journal that has been disseminating groundbreaking research in the field of parasitology since 2009. With an ISSN of 2090-0023 and an E-ISSN of 2090-0031, this journal strives to provide researchers, professionals, and students with accessible and high-impact studies that advance understanding of parasitic diseases and their epidemiology. The journal currently holds a Q3 ranking in Infectious Diseases and a Q2 ranking in Parasitology, indicating its significant contribution to the academic community. Furthermore, with a Scopus ranking placing it at #39 in Parasitology and #186 in Infectious Diseases, it plays an essential role in shaping research directions in these fields. As an open-access journal, Journal of Parasitology Research enhances the visibility and accessibility of published works, ensuring crucial findings reach a global audience. With a focus on innovative research, the journal welcomes submissions that explore both theoretical frameworks and practical applications in parasitology, making it an invaluable resource for those dedicated to combating parasitic infections.

CHEMICAL & PHARMACEUTICAL BULLETIN, published by the Pharmaceutical Society of Japan, has been a cornerstone in the fields of chemistry, drug discovery, and medicine since its inception in 1958. With an ISSN of 0009-2363, this esteemed journal offers a platform for the dissemination of innovative research and critical insights contributing to these dynamic disciplines. Housed in Tokyo, Japan, it is strategically poised to bridge the gap between chemical sciences and pharmaceutical applications. Although the journal operates under a traditional subscription model and does not currently offer open access, it maintains a solid reputation, evidenced by its Q3 category rankings in multiple relevant fields and its percentile positions in Scopus, specifically 48th in General Chemistry and 30th in Drug Discovery. Researchers, professionals, and students alike will find invaluable resources within its pages, as it diligently covers shifting paradigms and emerging methodologies critical to advancing both theoretical understanding and practical applications in the pharmaceutical realm.